Stock Research for PTCT

PTCT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

PTCT Stock Chart & Research Data

The PTCT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PTCT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


PTCT Due diligence Resources & Stock Charts

The PTCT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PTCT Detailed Price Forecast - CNN Money CNN View PTCT Detailed Summary - Google Finance
Yahoo View PTCT Detailed Summary - Yahoo! Finance Zacks View PTCT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View PTCT Trends & Analysis - Trade-Ideas Barrons View PTCT Major Holders - Barrons
NASDAQ View PTCT Call Transcripts - NASDAQ Seeking View PTCT Breaking News & Analysis - Seeking Alpha
Spotlight View PTCT Annual Report - CompanySpotlight.com OTC Report View PTCT OTC Short Report - OTCShortReport.com
TradeKing View PTCT Fundamentals - TradeKing Charts View PTCT SEC Filings - Bar Chart
WSJ View Historical Prices for PTCT - The WSJ Morningstar View Performance/Total Return for PTCT - Morningstar
MarketWatch View the Analyst Estimates for PTCT - MarketWatch CNBC View the Earnings History for PTCT - CNBC
StockMarketWatch View the PTCT Earnings - StockMarketWatch MacroAxis View PTCT Buy or Sell Recommendations - MacroAxis
Bullish View the PTCT Bullish Patterns - American Bulls Short Pains View PTCT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View PTCT Stock Mentions - StockTwits PennyStocks View PTCT Stock Mentions - PennyStockTweets
Twitter View PTCT Stock Mentions - Twitter Invest Hub View PTCT Investment Forum News - Investor Hub
Yahoo View PTCT Stock Mentions - Yahoo! Message Board Seeking Alpha View PTCT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for PTCT - SECform4.com Insider Cow View Insider Transactions for PTCT - Insider Cow
CNBC View PTCT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PTCT - OTC Markets
Yahoo View Insider Transactions for PTCT - Yahoo! Finance NASDAQ View Institutional Holdings for PTCT - NASDAQ


Stock Charts

FinViz View PTCT Stock Insight & Charts - FinViz.com StockCharts View PTCT Investment Charts - StockCharts.com
BarChart View PTCT Stock Overview & Charts - BarChart Trading View View PTCT User Generated Charts - Trading View




Latest Financial News for PTCT


PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted on Tuesday October 23, 2018

SOUTH PLAINFIELD, N.J., Oct. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on October 17, 2018 it approved non-statutory stock options to purchase an aggregate of 68,700 shares of its common stock to 13 new employees.  The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on October 17, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). Eight of the stock option awards have an exercise price of $39.73 per share, the closing price of PTC's common stock on October 17, 2018, the date of the grant.


Market Trends Toward New Normal in PTC Therapeutics, AeroVironment, Autodesk, Coca-Cola Bottling Co. Consolidated, Akers Biosciences, and TEGNA — Emerging Consolidated Expectations, Analyst Ratings
Posted on Tuesday October 23, 2018

NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.


PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2018 Financial Results
Posted on Monday October 22, 2018

SOUTH PLAINFIELD, N.J. , Oct. 22, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2018 financial ...


PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation
Posted on Saturday October 06, 2018

SOUTH PLAINFIELD, N.J., Oct. 6, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced preliminary data from the first international drug registry for Duchenne patients receiving Translarna™ (ataluren), underscoring the long-term clinical benefit of Translarna when used in routine clinical practice in delaying irreversible muscle loss in children with Duchenne caused by a nonsense mutation, when compared with published natural history. The data show that children and adolescents receiving Translarna in the real-world setting are continuing to walk years longer than untreated children, and are staying more physically able.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.